RxDoctor Payments Data

Luis Ragunton, MD

Internal Medicine · Aiea, HINPI 1598869067

Payments from drug & device makers

$3,011in general payments, 2019–2025

Across 150 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$491
  • AstraZeneca$473
  • Amgen$361
  • Pfizer$202
  • Biohaven Pharmaceutical Holding Company Ltd.$170
  • Amarin Pharma, Inc.$142
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,98399%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,011 in reported general payments places this provider in the 80th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$28,108
Medicare patients
68
Services billed
280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$30,998
RybelsusSemaglutide11$29,014
EliquisApixaban25$18,874
FarxigaDapagliflozin Propanediol16$18,591
Trijardy XrEmpaglifloz/Linaglip/Metformin12$7,238
SymbicortBudesonide/Formoterol Fumarate11$2,634
Rosuvastatin Calcium50$2,484
Atorvastatin Calcium74$1,543
Pravastatin Sodium64$1,486
Irbesartan37$1,168
Losartan Potassium47$1,005
Olmesartan Medoxomil14$1,001
Colchicine17$928
Amlodipine Besylate79$890
Gabapentin32$858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$491$60,01239 claims
AstraZenecaFarxiga, Symbicort$473$21,22527 claims
PfizerEliquis$202$18,87425 claims
Boehringer IngelheimTrijardy Xr$86$7,23812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →